GSK Invests $100 Million in Vaccine Manufacturing
Expansion at GSK’s Hamilton, MT site is designed to boost vaccine production capacity.
GlaxoSmithKline (GSK) announced plans to expand production capacity of key components of the adjuvant system used in several of the company’s vaccines, with an investment of $100 million in its manufacturing site in Hamilton, MT.
“For more than a decade, our Hamilton facility has supported GSK’s adjuvant system development program,” said Jack Bailey, president, US Pharmaceuticals, GSK in an April 24, 2019 press statement announcing the investment. “By expanding the adjuvant system production capabilities in Hamilton, we will continue to deliver long-term and sustainable supply for key vaccines, including SHINGRIX.”
The company reports that the site expansion is expected to add temporary construction and contracting jobs, as well as new permanent positions, including scientists, engineers, and manufacturing and quality professionals.
Hamilton is one of nine GSK manufacturing sites in the United States, and 86 sites globally.
Source: GSK
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
